EUVIMEDEUVIMED entdecken
Vergleichsstudie

Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?

Changwu Zhou, Chun Yang, Mengsu Zeng

Hepatology International · 2025

DOI: 10.1007/s12072-024-10730-1 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Hepatology International, 2025. Verfasst von Changwu Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Cholangiocarcinoma, Liver Neoplasms, Bile Duct Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Science Foundation of China, Clinical Research Plan of SHDC, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Whether there are differences in recurrence-free survival (RFS) prognosis between combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) cases with a small proportion of CCA components and HCC cases remains unknown. We aim to investigate the differences in RFS prognosis between cHCC-CCAs with a small proportion of CCA components and HCCs. METHODS: Patients with malignant liver neoplasms who underwent MRI and surgery were prospectively recruited. All cHCC-CCA patients were divided into different groups according to the ratio of CCA components. The primary end point was recurrence-free-survival. Cox regression analysis and Kaplan-Meier survival analysis was used to investigate and compare RFS prognosis. RESULTS: One hundred sixty-four cHCC-CCA cases and 271 HCC cases were enrolled. There was no significant difference in RFS prognosis between cHCC-CCA cases with a CCA component of 0.05). CONCLUSIONS: There were no significant differences in RFS prognosis, major HCC-favoring MRI features, and clinicopathological findings between cHCC-CCAs with a CCA component of < 10% and HCCs. Therefore, we suggest that cHCC-CCAs with pathological diagnosis of less than 10% of CCA components may be treated as HCCs in clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsBile Duct NeoplasmsHumansMaleFemaleMiddle AgedAgedMagnetic Resonance ImagingPrognosisProspective StudiesKaplan-Meier EstimateAdult

Stichwörter der Autor:innen

Liver neoplasmsMagnetic resonance imagingPrognosis

Autor:innen und Institutionen

  • Department of Radiology, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
  • Department of Radiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. dryangchun@hotmail.com.
  • Department of Radiology, Zhongshan Hospital, Fudan University, No. 180 Fenglin Road, Xuhui District, Shanghai, 200032, China. zengmengsu20210116@163.com.

Förderung

  • National Science Foundation of China
  • Clinical Research Plan of SHDC
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Zhou, C., Yang, C., & Zeng, M. (2025). Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?. Hepatology International. https://doi.org/10.1007/s12072-024-10730-1

Vancouver

Zhou C, Yang C, Zeng M. Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?. Hepatology International. 2025. doi:10.1007/s12072-024-10730-1

BibTeX
@article{Zhou2025,
  author = {Zhou, Changwu and Yang, Chun and Zeng, Mengsu},
  title = {Is it necessary to distinguish between combined hepatocellular carcinoma-cholangiocarcinoma with less than 10% of cholangiocarcinoma components versus hepatocellular carcinoma?},
  journal = {Hepatology International},
  year = {2025},
  doi = {10.1007/s12072-024-10730-1}
}
Kostenlos starten →